VistaGen Therapeutics, Inc.
VTGN
$2.22
-$0.12-5.13%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 234.00K | 183.00K | 84.00K | 197.30K | 411.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 234.00K | 183.00K | 84.00K | 197.30K | 411.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 234.00K | 183.00K | 84.00K | 197.30K | 411.00K |
| SG&A Expenses | 4.05M | 4.20M | 4.57M | 4.12M | 3.76M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.35M | 14.41M | 12.22M | 11.56M | 8.30M |
| Operating Income | -15.12M | -14.23M | -12.13M | -11.36M | -7.88M |
| Income Before Tax | -14.09M | -12.95M | -10.73M | -9.52M | -6.35M |
| Income Tax Expenses | -- | 7.00K | -- | 1.50K | -- |
| Earnings from Continuing Operations | -14.09M | -12.96M | -10.73M | -9.52M | -6.35M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.09M | -12.96M | -10.73M | -9.52M | -6.35M |
| EBIT | -15.12M | -14.23M | -12.13M | -11.36M | -7.88M |
| EBITDA | -15.08M | -14.19M | -12.10M | -11.33M | -7.85M |
| EPS Basic | -0.46 | -0.42 | -0.35 | -0.31 | -0.22 |
| Normalized Basic EPS | -0.29 | -0.26 | -0.22 | -0.19 | -0.14 |
| EPS Diluted | -0.46 | -0.42 | -0.35 | -0.31 | -0.22 |
| Normalized Diluted EPS | -0.29 | -0.26 | -0.22 | -0.19 | -0.14 |
| Average Basic Shares Outstanding | 30.71M | 30.63M | 30.60M | 30.52M | 29.39M |
| Average Diluted Shares Outstanding | 30.71M | 30.63M | 30.60M | 30.52M | 29.39M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |